Naturally available hypericin undergoing electron transfer for type I

photodynamic and photothermal synergistic therapy

Zhen Ke†a, Aize Xie†b, Jianjiao Chena, Zhenyuan Zoua, Lei Shen*c, Yansong Dai*d,

Dengfeng Zou*a

a. School of Pharmacy, Guilin Medical University, Guilin 541004, Guangxi, P.R. China, Email: <u>zdf1226@126.com</u>

b. The First Affiliated Hospital of Guangxi Medical University, Nanning 530021, Guangxi, P.R. China

c. Jiangsu Laboratory of Advanced Functional Material, Department of Chemistry and Material Engineering, Changshu Institute of Technology, Changshu 215500, Jiangsu, P.R. China Email: <u>leishen@cslg.edu.cn</u>

d. Virginia University of Integrative Medicine, Fairfax, 22031, Virginia, USA. Email: daiyansong@gmail.com

†: *These authors contribute equally to the work*



Figure S1 ¹HNMR spectra of HC in CDCl₃



Figure S2 (a)¹³CNMR of HC in CDCl₃



(b)¹³CNMR of HC in CDCl₃ from 130 to 90 ppm



Peak No Width 1/2 (sec) Peak Name Area (counts) Result () Ret. Time (min) 115754 0.0705 3.311 8.6 0.2852 4.304 9.7 2 468341 3 501820 0.3056 6.918 12.4 4 162519536 98.9725 7.907 24.0 5 209014 0.1273 10.061 0.0 0.2390 392380 11.055 0.0 6 Totals 164206848 100.0001

Figure S3 HPLC of HC



Figure S4 (a) Degradation of DPBF under the presence of **MB** with irradiation; (b) linear fitting of the absorbance.



Figure S5 Fluorescence change of (a) DHR123; (b) HPF and (c) SOSG with irradiation. (660 nm, 0.1 W/cm²).



Figure S6 (A) Biodistribution of HC NPs in tumor, heart, liver, spleen, lung and kidney after 48 h post injection; (B) Fluorescence intensity of tumor, heart, liver, spleen, lung and kidney. (n = 3)



Figure S7 Time dependent drug concentration of **HC** NPs in mice (n = 6)